http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 17 Feb 2026 06:11:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005124.html si-local-file:///var/storage/secattach/20260217/26005124.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005124.html Tue, 17 Feb 2026 06:11:00 -0500 O.00652373 VANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005124.html si-local-file:///var/storage/secattach/20260217/26005124.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005124.html Tue, 17 Feb 2026 06:11:00 -0500 O.00652373 VANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005129.html si-local-file:///var/storage/secattach/20260217/26005129.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005129.html Tue, 17 Feb 2026 06:11:00 -0500 O.00652373 VANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005129.html si-local-file:///var/storage/secattach/20260217/26005129.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Feb+15++Filed+by%3A+Williams+Gregg/26005129.html Tue, 17 Feb 2026 06:11:00 -0500 O.00652373 VANI http://www.streetinsider.com/Corporate+News/Cortigent+presents+6-year+study+results+for+vision+implant+device/25912220.html <p>Vivani Medical Inc. (NASDAQ: VANI) announced that its subsidiary Cortigent presented results from a 6-year early feasibility study of the Orion Visual Cortical Prosthesis System at the North American Neuromodulation Society annual meeting in Las Vegas.</p><p>The study involved six subjects who received implants between January 2018 and January 2019, with the study concluding in March 2025. The Orion system uses a wirelessly powered implantable pulse generator connected to 60 micro-electrodes placed on the brain's visual cortex surface to provide visual perception to blind patients.</p><p>All subjects demonstrated improvement in visual function tests when the system was activated compared to when it http://www.streetinsider.com/Corporate+News/Cortigent+presents+6-year+study+results+for+vision+implant+device/25912220.html Thu, 29 Jan 2026 07:30:44 -0500 VANI http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Press+Releases/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html <p align="center"><em>Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology </em></p> <p align="center"><em>Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind</em></p> <p align="center"><em>The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke</em></p> <p>ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), http://www.streetinsider.com/Globe+Newswire/Vivani+Subsidiary+Cortigent+Presents+Promising+6-Year+Early+Feasibility+Study+Results+for+the+Orion+System+at+NANS+2026/25912205.html Thu, 29 Jan 2026 07:30:00 -0500 A.10255573 O.00652373 O.20227671 VANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+27++Filed+by%3A+Williams+Gregg/25905786.html si-local-file:///var/storage/secattach/20260128/25905786.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+27++Filed+by%3A+Williams+Gregg/25905786.html Wed, 28 Jan 2026 10:01:00 -0500 O.00652373 VANI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+27++Filed+by%3A+Williams+Gregg/25905786.html si-local-file:///var/storage/secattach/20260128/25905786.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+27++Filed+by%3A+Williams+Gregg/25905786.html Wed, 28 Jan 2026 10:01:00 -0500 O.00652373 VANI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+25/25900759.html si-local-file:///var/storage/secattach/20260127/25900759.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+25/25900759.html Tue, 27 Jan 2026 16:11:00 -0500 O.00652373 VANI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+25/25900759.html si-local-file:///var/storage/secattach/20260127/25900759.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vivani+Medical%2C+Inc.++++++For%3A+Jan+25/25900759.html Tue, 27 Jan 2026 16:11:00 -0500 O.00652373 VANI http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+closes+%244.5+million+stock+offering/25900559.html <p>Vivani Medical, Inc. (NASDAQ: VANI) completed a stock offering that raised approximately $4.5 million in gross proceeds before fees and expenses, according to a company statement.</p> <p>The clinical-stage biopharmaceutical company sold 1,689,200 shares of common stock at $1.48 per share through a registered direct offering. The company also completed a concurrent private placement of 1,351,351 shares at the same price to Gregg Williams, chairman of Vivani's board of directors.</p> <p>Both transactions were priced at-the-market under Nasdaq Stock Market rules. ThinkEquity served as the sole placement agent for the registered direct offering.</p> <p>Vivani stated it plans to use the net proceeds to fund research http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+closes+%244.5+million+stock+offering/25900559.html Tue, 27 Jan 2026 16:05:09 -0500 VANI http://www.streetinsider.com/Press+Releases/Vivani+Medical%2C+Inc.+Announces+Closing+of+Common+Stock+Offering/25900536.html <p align="justify">ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company’s board of directors. Gross proceeds from the two transactions were approximately $4.5 million, http://www.streetinsider.com/Press+Releases/Vivani+Medical%2C+Inc.+Announces+Closing+of+Common+Stock+Offering/25900536.html Tue, 27 Jan 2026 16:05:00 -0500 VANI http://www.streetinsider.com/Globe+Newswire/Vivani+Medical%2C+Inc.+Announces+Closing+of+Common+Stock+Offering/25900536.html <p align="justify">ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company’s board of directors. Gross proceeds from the two transactions were approximately $4.5 million, http://www.streetinsider.com/Globe+Newswire/Vivani+Medical%2C+Inc.+Announces+Closing+of+Common+Stock+Offering/25900536.html Tue, 27 Jan 2026 16:05:00 -0500 VANI http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Vivani+Medical%2C+Inc.+++++++++++++++++/25895504.html si-local-file:///var/storage/secattach/20260127/25895504.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Vivani+Medical%2C+Inc.+++++++++++++++++/25895504.html Tue, 27 Jan 2026 06:03:00 -0500 O.00652373 VANI http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Vivani+Medical%2C+Inc.+++++++++++++++++/25895504.html si-local-file:///var/storage/secattach/20260127/25895504.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Vivani+Medical%2C+Inc.+++++++++++++++++/25895504.html Tue, 27 Jan 2026 06:03:00 -0500 O.00652373 VANI http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+prices+stock+offering+at+%241.48+per+share/25889060.html <p>Vivani Medical, Inc. (NASDAQ: VANI) announced the pricing of a registered direct offering of 1,689,200 shares of common stock at $1.48 per share. The company also priced a concurrent private placement of 1,351,351 shares at the same price, purchased by Gregg Williams, chairman of the company's board of directors.</p> <p>The combined offerings are expected to generate gross proceeds of approximately $4.5 million before deducting placement agent fees and estimated offering expenses. Both the registered offering and private placement were priced at-the-market under Nasdaq Stock Market rules and are expected to close on or about January 27, 2026, subject to customary closing http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+prices+stock+offering+at+%241.48+per+share/25889060.html Sun, 25 Jan 2026 23:36:39 -0500 A.19657706 O.00652373 O.36250936 VANI http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+prices+stock+offering+at+%241.48+per+share/25889060.html <p>Vivani Medical, Inc. (NASDAQ: VANI) announced the pricing of a registered direct offering of 1,689,200 shares of common stock at $1.48 per share. The company also priced a concurrent private placement of 1,351,351 shares at the same price, purchased by Gregg Williams, chairman of the company's board of directors.</p> <p>The combined offerings are expected to generate gross proceeds of approximately $4.5 million before deducting placement agent fees and estimated offering expenses. Both the registered offering and private placement were priced at-the-market under Nasdaq Stock Market rules and are expected to close on or about January 27, 2026, subject to customary closing http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+prices+stock+offering+at+%241.48+per+share/25889060.html Sun, 25 Jan 2026 23:36:39 -0500 A.19657706 O.00652373 O.36250936 VANI http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+prices+stock+offering+at+%241.48+per+share/25889060.html <p>Vivani Medical, Inc. (NASDAQ: VANI) announced the pricing of a registered direct offering of 1,689,200 shares of common stock at $1.48 per share. The company also priced a concurrent private placement of 1,351,351 shares at the same price, purchased by Gregg Williams, chairman of the company's board of directors.</p> <p>The combined offerings are expected to generate gross proceeds of approximately $4.5 million before deducting placement agent fees and estimated offering expenses. Both the registered offering and private placement were priced at-the-market under Nasdaq Stock Market rules and are expected to close on or about January 27, 2026, subject to customary closing http://www.streetinsider.com/Equity+Offerings/Vivani+Medical+prices+stock+offering+at+%241.48+per+share/25889060.html Sun, 25 Jan 2026 23:36:39 -0500 A.19657706 O.00652373 O.36250936 VANI